Shares of BrightSpring popped 5.0% on Thursday to close at $72.84.
Revenue climbed to $12.9B in 2025, up 28.2% year over year, and both operating and net margins moved higher.
"Net cash used in financing activities was $94.3 million for the six months ended June 30, 2025, primarily attributable to repayments on our long-term debt of $23.7 million, net repayments on our Revolving Credit Facility of $63.3 million, payment of financing lease obligations of $6.7 million, and other financing activities." (BrightSpring / 10-Q / 2026-07-31)
The filing shows some debt paydown, revolver activity, and a roughly $94.3 million cash outflow on financing in the first half of 2025.
Key 2025 results: operating margin rose to 2.3% and net margin to 1.5% after a period when both were basically flat. Operating cash flow covered net income by 2.57x last year — which is to say, the business is generating cash faster than it posts accounting profit.
"The closing of the remaining three branches is expected to occur in fiscal year 2026, subject to customary regulatory approvals and other closing conditions." (BrightSpring / 10-Q / 2026-05-01)
Management is also sorting some structural pieces — branch closings and regulatory steps that will take time to finalize and show up in the numbers.
If you map the risks and rewards mechanically, the scenarios in the filings put revenue momentum front-and-center. The bull and base cases both rely on the same revenue CAGR of 18.7% and an exit P/E of 84.0x; the bear case assumes slower top-line growth and a much lower exit multiple of 22.6x. The filing calls the bull-to-bear spread moderate (~111 points), and notes that most of that gap comes from which exit multiple the market assigns.
The company is growing fast and edging margins higher — the long-case evidence the filing highlights — but it is also diluting shareholders (diluted shares increased 13.9% in 2025) and flagging credit/interest-rate exposure repeatedly across filings. The balance sheet reads like this on paper: market cap $16.0B, enterprise value $18.4B, net debt $2.4B, and the stock trades at a P/E of 84.0x (EV/sales 1.4x).
The data set makes both arguments easy to show. On one side, revenue up 28.2%, operating margin up 1.2 percentage points, net margin up 1.7 percentage points, and operating cash flow comfortably above net income. On the other side, nearly 14% more diluted shares in the last year and repeated financing-line notes across five filings that cite credit and interest-rate pressures.
Investors are weighing strong organic growth and improving cash generation against valuation: a P/E of 84.0x. The filings lay out the mechanics; the market is deciding how much multiple that momentum deserves.
Figures cited from BrightSpring Health Services 10-Q and 10-K filings.